RJ029

RJ029 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Risen Pharma for the treatment of metabolic diseases. The drug utilizes a dual-targeting approach, although the specific biological targets remain undisclosed by the sponsor. As an siRNA molecule, RJ029 is designed to silence the expression of specific genes involved in metabolic dysfunction, potentially offering a long-acting treatment option for conditions such as obesity, dyslipidemia, or type 2 diabetes. The program is part of Risen's dedicated investment in the siRNA field, which focuses on creating next-generation therapeutics for chronic conditions.